The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. (Q39573304)
Jump to navigation
Jump to search
scientific article published on 21 March 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. |
scientific article published on 21 March 2011 |
Statements
The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts (English)
Marie-Christine Etienne-Grimaldi
Jean-Louis Fischel
Anne Sudaka
Nicolas Toussan
Patricia Formento
Gérard Milano
21 March 2011